ABCL
AbCellera Biologics Inc.
There isn't enough reported data to score ABCL yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ABCL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
ABCL's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABCL PE Valuation
ABCL has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ABCL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ABCL's losses to grow, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ABCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.48 | +$0.09 |
| Q2 2026 | -$0.54 | +$0.01 |
| Q1 2026 | -$0.48 | +$0.08 |
| Q4 2025 | -$0.49 | +$0.06 |
| Q3 2025 | -$0.57 | +$0.03 |
| Q2 2025 | -$0.55 | -$0.02 |
| Q1 2025 | -$0.56 | -$0.05 |
| Q4 2024 | -$0.55 | -$0.04 |
ABCL is still losing money, but less than at its worst: $0.48 per share over the past year, against $0.60 at its worst in late 2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ABCL on earnings quality, reporting a profit while its opponent remains loss making.
ABCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.6M | +19% |
| Q2 2026 | $4.1M | -76% |
| Q1 2026 | $8.3M | +96% |
| Q4 2025 | $44.9M | +788% |
| Q3 2025 | $9M | +38% |
| Q2 2025 | $17.1M | +133% |
| Q1 2025 | $4.2M | -57% |
| Q4 2024 | $5.1M | -45% |
ABCL's revenue is recovering but still below its 2022 peak: $11M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -501% | +351 points |
| Q2 2026 | -1550% | -1260 points |
| Q1 2026 | -692% | +788 points |
| Q4 2025 | -64% | +1377 points |
| Q3 2025 | -852% | +588 points |
| Q2 2025 | -290% | +986 points |
| Q1 2025 | -1480% | -928 points |
| Q4 2024 | -1441% | -721 points |
ABCL's operating margin was −501% last quarter, up 351 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ABCL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ABCL on profitability, with a higher operating margin.
ABCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.3M | +$86.8M |
| Q2 2026 | $23.8M | +$69.6M |
| Q1 2026 | -$37.4M | -$15.2M |
| Q4 2025 | -$44.6M | -$21M |
| Q3 2025 | -$61.5M | -$14.1M |
| Q2 2025 | -$45.8M | +$4.3M |
| Q1 2025 | -$22.2M | +$43.7M |
| Q4 2024 | -$23.6M | +$10.4M |
ABCL has burned cash in most quarters: −$33M over the past year, against −$153M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ABCL on cash generation, producing positive trailing cash flow while its opponent burns cash.
ABCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +12.5M shares |
| 1 year | +6.4% | +19.2M shares |
| 3 years | +9.9% | +28.6M shares |
| 5 years | +14% | +39.1M shares |
| Available history | +34% | +80.3M shares |
ABCL has 318M diluted shares, up 6.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ABCL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ABCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -1.6x | Net Cash |
| Q3 2022 | -1.1x | Net Cash |
| Q2 2022 | -2.8x | Net Cash |
| Q1 2022 | -1.9x | Net Cash |
| Q4 2021 | -2.2x | Net Cash |
| Q4 2020 | -3.5x | Net Cash |
| Q3 2020 | -12.0x | Net Cash |
| Q2 2020 | -14.9x | Net Cash |
ABCL has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ABCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.4 | Neutral |
| Stochastic | 62.7 | Neutral |
ABCL's weekly RSI is 61 (neutral) and its Stochastic is 63 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ABCL PE vs Healthcare Sector
| Metric | ABCL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ABCL has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ABCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.3 | 5.5% below |
| 20 week MA | $10.3 | 12% above |
| 50 week MA | $6.63 | 75% above |
| 100 week MA | $5.07 | 129% above |
| 200 week MA | $5.06 | 130% above |
ABCL's trend is up, with a small recent dip: it's below only its 8-week average, and 130% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ABCL on trend strength, trading above more of its moving averages.
ABCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $42.4 | -28% |
| 2021 | $42.4 | $14.9 | -65% |
| 2022 | $14.9 | $10.3 | -31% |
| 2023 | $10.3 | $5.71 | -45% |
| 2024 | $5.71 | $2.99 | -48% |
| 2025 | $2.99 | $3.58 | +20% |
| 2026 YTD | $3.58 | $11.6 | +225% |
ABCL has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.